sábado, 13 de junio de 2020

Fact Sheet for Healthcare Providers: Dimension EXL SARS-CoV-2 Total Antibody Assay (CV2T) | NLM

Disaster Information Management Research Center | NLM

Disaster Information and Emergency Response

06/08/2020 12:00 AM EDT


Source: U.S. Food and Drug Administration (FDA). Published: 6/8/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of Dimension EXL SARS-CoV-2 Total Antibody Assay (CV2T) (Dimension EXL CV2T). Dimension EXL CV2T is authorized for the detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (dipotassium EDTA and lithium heparin). (PDF)

No hay comentarios: